Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00467233
Other study ID # STU679
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date May 2007
Est. completion date June 2009

Study information

Verified date November 2021
Source Northwestern University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The objective of this study is to evaluate laser treatment and acid peel for the treatment of melasma.


Description:

The purpose of this study is to evaluate the safety and efficacy of laser treatment and acid peel for the treatment of melasma.


Recruitment information / eligibility

Status Completed
Enrollment 15
Est. completion date June 2009
Est. primary completion date June 2009
Accepts healthy volunteers No
Gender All
Age group 18 Years to 75 Years
Eligibility Inclusion Criteria: - Diagnosis of melasma lesion measuring at least 4 square centimeters. - Age 18-75 years. - Good health. - Willingness and ability to understand and provide informed consent for participation in the study. - Ability to communicate with the investigator. - Must be willing to forgo other treatment options for melasma during the course of the study. Exclusion Criteria: - Inability to understand the protocol or to give informed consent. - Mental illness. - Under 18 years of age and over 75 years of age. - Laser treatment in the last 6 months before enrollment. - Isotretinoin within the past year. - Lidocaine allergy. - History of herpes simplex viral infection. - Concurrent active disease to facial area (i.e acne). - Bleeding disorder. - History of abnormal wound healing. - History of abnormal scarring.

Study Design


Related Conditions & MeSH terms


Intervention

Procedure:
Laser Treatment
Laser treatment to half of the face at each study visit
Acid Peel
Acid peel to half of the face at each study visit

Locations

Country Name City State
United States Northwestern University Feinberg School of Medicine, Department of Dermatology Chicago Illinois

Sponsors (1)

Lead Sponsor Collaborator
Northwestern University

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary MASI 20 weeks
Secondary Safety 20 weeks
See also
  Status Clinical Trial Phase
Completed NCT05013801 - A Clinical Study to Evaluate the Effect of Facial Serum Q69 in Moderating the Appearance of Mild to Moderate Melasma N/A
Recruiting NCT06174545 - Effectiveness and Safety of Pigment Solution Program (PSP) as Adjuvant Therapy in Melasma N/A
Completed NCT01695356 - Ultraviolet and UV-Visible Light Photoprotection for the Treatment of Melasma Phase 4
Recruiting NCT06278948 - Efficacy and Tolerability of Test Product Versus Cysteamine 5% in Treatment of Facial Epidermal Melasma N/A
Not yet recruiting NCT05911698 - Fractional co2 Laser Followed by Either Vitamin c or Tranexamic Acid in Treatment of Melasma. N/A
Recruiting NCT05656833 - Combination Topical Cysteamine and Fractional 1927nm Low-Powered Diode Laser for Treatment of Facial Melasma N/A
Recruiting NCT04597203 - Efficacy and Safety of Using Combination of 755-nm Picosecond Alexandrite Laser and 2% Hydroquinone Compared With 2% Hydroquinone Alone for the Treatment of Melasma: a Randomized Split-face Controlled Trial N/A
Completed NCT02138539 - Evaluation of an Herbal-Based De-Pigmenting System Phase 4
Recruiting NCT01661556 - Clinical Trial of Hydroquinone Versus Miconazol in Melasma Phase 4
Completed NCT01001624 - Melanil in the Treatment of Melasma Phase 3
Terminated NCT03415685 - Lutronic PicoPlus Exploratory Clinical Trial N/A
Recruiting NCT04765930 - Combined Q-switched Nd:YAG Laser and Platelet Rich Plasma Versus Q- Switched Nd:YAG Laser Alone in Melasma N/A
Completed NCT04137263 - Study Evaluating the Efficacy of DOSE Formulations in Treating Melasma and Cutaneous Signs of Aging N/A
Recruiting NCT03686787 - Oral Tranexamic Acid and Laser for Treatment of Melasma Phase 4
Completed NCT05969587 - Cysteamine Compared to Hydroquinone in Melasma Phase 3
Completed NCT00472966 - Efficacy and Safety of Therapy With Tri-Luma® Cream in Sequence With Glycolic Acid Peels for Melasma Phase 4
Completed NCT00500162 - Comparison of Two Tri-Luma® Maintenance Regimens in the Treatment of Melasma Phase 4
Completed NCT05884151 - Comparison of Intralesional Tranexamic Acid and Platelets Rich Plasma in the Treatment of Melasma Phase 1
Completed NCT05887219 - Comparison of Azelaic Acid 20 % Cream Versus Hydroquinone 4% Cream as an Adjuvant to Oral Tranexamic Acid in Melasma Phase 1
Recruiting NCT03308370 - Platelet Rich Plasma in Treatment of Melasma Phase 3